Weight Loss Showdown: Mounjaro (Tirzepatide) Trounces Wegovy in Head-to-Head Trial

In a nutshell * Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of treatment Tirzepatide users experienced greater waistline reduction (7.2 inches vs. 5.1 inches) and more significant improvements in health markers * Both medications caused similar side effects, but fewer people discontinued tirzepatide due to stomach issues (2.7% vs. 5.6%) ======================================================================== NEW YORK — For the first time, scientists have pitted the two most popular weight loss drugs against each other in a direct competition – and one clearly dominates. A new study led by Weill Cornell Medicine researchers reveals that tirzepatide (Mounjaro,...